Wednesday, March 23, 2022
1:30PM – 2:30PM ET [Please note new meeting time]
This TeleECHO program is 1:30PM Eastern, 12:30PM Central, 11:30AM Mountain and 10:30AM Pacific.
This live virtual TeleECHO program will explore the management of ocular toxicities and other adverse events related to treatment of relapsed and refractory multiple myeloma (RRMM). A brief didactic presentation will discuss how and why these adverse events occur. The importance of Risk Evaluation and Mitigation Strategy (REMS) programs for monitoring your patients for corneal changes and other effects of later-line therapy for multiple myeloma will also be presented. Interactive case studies will illustrate strategies for choosing therapy and for managing treatment-related adverse events in the RRMM setting.
Amrita Krishnan, MD
Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research
Professor, Department of Hematology & Hematopoietic Cell Transplantation
Chief, Division of Multiple Myeloma
Department of Hematology and Hematopietic Cell Transplantation
City of Hope Cancer Center
After completing the CME activity, learners should be better able to:
- Summarize the mechanism of therapies in management of heavily relapsed/refractory multiple myeloma and how therapeutic mechanisms relate to potential adverse events
- Recognize challenges in identification of potential adverse events in multiple myeloma, including corneal adverse events, and evaluate best practice for detection and management
- Evaluate the benefits and potential adverse events associated with later-line multiple myeloma therapy, including corneal adverse events, in the context of REMS programs
This activity is designed to meet the educational needs of multiple myeloma specialists, general oncologists, oncology nurses, clinical pharmacists, and ophthalmologists. Through participation in this programming, the audience will be better able to manage potential adverse events associated with later-line management of multiple myeloma, including potential ocular adverse events, in an interdisciplinary fashion, consistent with REMS educational requirements.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the management of patients with multiple myeloma.
1.0 ANCC Contact Hour
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at [email protected].
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]